Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis
Classical Hodgkin lymphoma (HL) patients presenting a relapsed/refractory (R/R) disease are currently managed with salvage chemotherapy followed by autologous stem cell transplantation (ASCT). However, almost 25–30% of these patients fail to achieve a complete response (CR) with standard salvage reg...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/4/982 |
| _version_ | 1797482070308552704 |
|---|---|
| author | Fulvio Massaro Nathalie Meuleman Dominique Bron Marie Vercruyssen Marie Maerevoet |
| author_facet | Fulvio Massaro Nathalie Meuleman Dominique Bron Marie Vercruyssen Marie Maerevoet |
| author_sort | Fulvio Massaro |
| collection | DOAJ |
| description | Classical Hodgkin lymphoma (HL) patients presenting a relapsed/refractory (R/R) disease are currently managed with salvage chemotherapy followed by autologous stem cell transplantation (ASCT). However, almost 25–30% of these patients fail to achieve a complete response (CR) with standard salvage regimens. In this retrospective study, we evaluated the efficacy of a combination of brentuximab vedotin (BV) and pembrolizumab in a series of HL patients presenting with a high-risk, multi-refractory disease. Patients achieving a Deauville score ≤4 proceeded to ASCT consolidation. After ASCT, patients received BV as maintenance for a total of 16 administrations. We collected data from 10 patients with a median age of 30.7 years. At a median follow-up of 16.5 months, we reported a complete metabolic remission (CMR) in eight patients (80%), with seven patients (70%) directly proceeding to ASCT (the other two patients in CMR are still undergoing treatment). BV consolidation was started in six patients and completed by three patients (one ongoing, two interruption). Two patients (20%) presented a progressive disease (PD) and subsequently died, while the others are still in CMR. The BV and pembrolizumab combination is a very effective bridge treatment to ASCT for high-risk R/R HL patients. |
| first_indexed | 2024-03-09T22:24:00Z |
| format | Article |
| id | doaj.art-5591400dd2664c379f5e4d9d210e35fe |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T22:24:00Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-5591400dd2664c379f5e4d9d210e35fe2023-11-23T19:09:30ZengMDPI AGCancers2072-66942022-02-0114498210.3390/cancers14040982Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective AnalysisFulvio Massaro0Nathalie Meuleman1Dominique Bron2Marie Vercruyssen3Marie Maerevoet4Department of Haematology, Institut Jules Bordet (ULB), 1070 Brussels, BelgiumDepartment of Haematology, Institut Jules Bordet (ULB), 1070 Brussels, BelgiumDepartment of Haematology, Institut Jules Bordet (ULB), 1070 Brussels, BelgiumDepartment of Haematology, Institut Jules Bordet (ULB), 1070 Brussels, BelgiumDepartment of Haematology, Institut Jules Bordet (ULB), 1070 Brussels, BelgiumClassical Hodgkin lymphoma (HL) patients presenting a relapsed/refractory (R/R) disease are currently managed with salvage chemotherapy followed by autologous stem cell transplantation (ASCT). However, almost 25–30% of these patients fail to achieve a complete response (CR) with standard salvage regimens. In this retrospective study, we evaluated the efficacy of a combination of brentuximab vedotin (BV) and pembrolizumab in a series of HL patients presenting with a high-risk, multi-refractory disease. Patients achieving a Deauville score ≤4 proceeded to ASCT consolidation. After ASCT, patients received BV as maintenance for a total of 16 administrations. We collected data from 10 patients with a median age of 30.7 years. At a median follow-up of 16.5 months, we reported a complete metabolic remission (CMR) in eight patients (80%), with seven patients (70%) directly proceeding to ASCT (the other two patients in CMR are still undergoing treatment). BV consolidation was started in six patients and completed by three patients (one ongoing, two interruption). Two patients (20%) presented a progressive disease (PD) and subsequently died, while the others are still in CMR. The BV and pembrolizumab combination is a very effective bridge treatment to ASCT for high-risk R/R HL patients.https://www.mdpi.com/2072-6694/14/4/982Hodgkin lymphomaantibody-drug conjugateimmune checkpoint inhibitionbrentuximab vedotinpembrolizumabsalvage therapy |
| spellingShingle | Fulvio Massaro Nathalie Meuleman Dominique Bron Marie Vercruyssen Marie Maerevoet Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis Cancers Hodgkin lymphoma antibody-drug conjugate immune checkpoint inhibition brentuximab vedotin pembrolizumab salvage therapy |
| title | Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis |
| title_full | Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis |
| title_fullStr | Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis |
| title_full_unstemmed | Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis |
| title_short | Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis |
| title_sort | brentuximab vedotin and pembrolizumab combination in patients with relapsed refractory hodgkin lymphoma a single centre retrospective analysis |
| topic | Hodgkin lymphoma antibody-drug conjugate immune checkpoint inhibition brentuximab vedotin pembrolizumab salvage therapy |
| url | https://www.mdpi.com/2072-6694/14/4/982 |
| work_keys_str_mv | AT fulviomassaro brentuximabvedotinandpembrolizumabcombinationinpatientswithrelapsedrefractoryhodgkinlymphomaasinglecentreretrospectiveanalysis AT nathaliemeuleman brentuximabvedotinandpembrolizumabcombinationinpatientswithrelapsedrefractoryhodgkinlymphomaasinglecentreretrospectiveanalysis AT dominiquebron brentuximabvedotinandpembrolizumabcombinationinpatientswithrelapsedrefractoryhodgkinlymphomaasinglecentreretrospectiveanalysis AT marievercruyssen brentuximabvedotinandpembrolizumabcombinationinpatientswithrelapsedrefractoryhodgkinlymphomaasinglecentreretrospectiveanalysis AT mariemaerevoet brentuximabvedotinandpembrolizumabcombinationinpatientswithrelapsedrefractoryhodgkinlymphomaasinglecentreretrospectiveanalysis |